AstraZeneca PLC $AZN Shares Sold by Foresight Group Ltd Liability Partnership

Foresight Group Ltd Liability Partnership reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 171,086 shares of the company’s stock after selling 24,806 shares during the quarter. AstraZeneca comprises about 2.0% of Foresight Group Ltd Liability Partnership’s investment portfolio, making the stock its 23rd largest holding. Foresight Group Ltd Liability Partnership’s holdings in AstraZeneca were worth $13,126,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Chapin Davis Inc. raised its position in shares of AstraZeneca by 3.3% during the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after buying an additional 120 shares in the last quarter. CoreCap Advisors LLC increased its stake in shares of AstraZeneca by 30.6% during the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after acquiring an additional 125 shares during the period. Highline Wealth Partners LLC raised its holdings in AstraZeneca by 32.0% during the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after purchasing an additional 129 shares in the last quarter. Traub Capital Management LLC raised its holdings in AstraZeneca by 3.3% during the third quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock worth $316,000 after purchasing an additional 130 shares in the last quarter. Finally, Aaron Wealth Advisors LLC lifted its position in AstraZeneca by 0.6% in the third quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after purchasing an additional 136 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca News Summary

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Reported full‑year 2025 revenue rose ~8% to $58.7B with product sales up ~9%; company cites sustained pipeline delivery underpinning growth. AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth
• Positive Sentiment: Q4 came in slightly ahead of consensus (Q4 revenue ≈ $15.5B) with cancer drugs highlighted as key drivers of the beat. AstraZeneca rises as cancer drugs power Q4 beat
• Positive Sentiment: Company forecasts 2026 revenue growth in the mid‑to‑high single digits and core EPS growth in the low‑double digits, driven by cancer and cardiovascular franchises and expansion in the U.S. and China. Drugmaker AstraZeneca forecasts sales and profit growth in 2026
• Neutral Sentiment: Management says growth is progressing toward its long‑term ~$80B target, signaling continued strategic execution but leaving timing uncertainty. AstraZeneca delivers continued growth toward $80 billion target
• Negative Sentiment: Analysts and company commentary flagged cost and margin pressures that could temper near‑term profitability despite revenue growth. AstraZeneca’s growth engine stays on track despite cost pressures
• Negative Sentiment: Valuation is elevated (background P/E ~62.6), which can prompt profit‑taking or greater sensitivity to any guidance/margin misses. AstraZeneca Forecasts Continued Growth on Pipeline Strength

AstraZeneca Trading Down 2.4%

NASDAQ:AZN opened at $188.40 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 1-year low of $122.48 and a 1-year high of $193.97. The firm has a market capitalization of $292.19 billion, a price-to-earnings ratio of 62.59, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The stock has a fifty day simple moving average of $103.79 and a 200 day simple moving average of $89.45.

Analyst Ratings Changes

AZN has been the topic of several research analyst reports. HSBC reiterated a “buy” rating and set a $108.00 price target on shares of AstraZeneca in a research report on Wednesday, December 10th. Wall Street Zen lowered AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Citigroup assumed coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.